175 related articles for article (PubMed ID: 34154869)
1. Feasibility and acceptability of a digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
Langdon KJ; Scherzer C; Ramsey S; Carey K; Rich J; Ranney ML
J Subst Abuse Treat; 2021 Dec; 131():108538. PubMed ID: 34154869
[TBL] [Abstract][Full Text] [Related]
2. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
[TBL] [Abstract][Full Text] [Related]
3. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
Schuman-Olivier Z; Borodovsky JT; Steinkamp J; Munir Q; Butler K; Greene MA; Goldblatt J; Xie HY; Marsch LA
Addict Sci Clin Pract; 2018 Sep; 13(1):21. PubMed ID: 30249279
[TBL] [Abstract][Full Text] [Related]
4. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
[TBL] [Abstract][Full Text] [Related]
5. Acceptability, language, and structure of text message-based behavioral interventions for high-risk adolescent females: a qualitative study.
Ranney ML; Choo EK; Cunningham RM; Spirito A; Thorsen M; Mello MJ; Morrow K
J Adolesc Health; 2014 Jul; 55(1):33-40. PubMed ID: 24559973
[TBL] [Abstract][Full Text] [Related]
6. Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder.
Peter SC; Murphy JG; Witkiewitz K; Hand SB; Thomas F; Johnson KC; Cowan R; Harris M; Derefinko KJ
Trials; 2023 Mar; 24(1):237. PubMed ID: 36991453
[TBL] [Abstract][Full Text] [Related]
7. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
8. Enhancing distress tolerance to uplift motivation in recovery: Results from an open development trial.
Bhuptani PH; Block A; Jiménez Muñoz P; Bello MS; Ramsey S; Ranney M; Carey K; Rich J; Langdon K
Digit Health; 2023; 9():20552076231158575. PubMed ID: 36845079
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and Acceptability of a Digital Health Intervention to Promote Continued Engagement in Medication for Opioid Use Disorder Following Release From Jail/Prison.
Langdon KJ; Jiménez Muñoz P; Block A; Scherzer C; Ramsey S
Subst Abuse; 2022; 16():11782218221127111. PubMed ID: 36188441
[TBL] [Abstract][Full Text] [Related]
10. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
[TBL] [Abstract][Full Text] [Related]
11. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
[TBL] [Abstract][Full Text] [Related]
13. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
14. Text message content preferences to improve buprenorphine maintenance treatment in primary care.
Tofighi B; Grossman E; Bereket S; D Lee J
J Addict Dis; 2016; 35(2):92-100. PubMed ID: 26670868
[TBL] [Abstract][Full Text] [Related]
15. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
[TBL] [Abstract][Full Text] [Related]
16. Study design to evaluate a group-based therapy for support persons of adults on buprenorphine/naloxone.
Osilla KC; Becker K; Ecola L; Hurley B; Manuel JK; Ober A; Paddock SM; Watkins KE
Addict Sci Clin Pract; 2020 Jul; 15(1):25. PubMed ID: 32653029
[TBL] [Abstract][Full Text] [Related]
17. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
18. Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.
Rudolph KE; Shulman M; Fishman M; Díaz I; Rotrosen J; Nunes EV
Addiction; 2022 Mar; 117(3):637-645. PubMed ID: 34338389
[TBL] [Abstract][Full Text] [Related]
19. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
20. Perceptions of medications, program settings, and drug use histories among individuals engaged in treatment for opioid use disorder.
Scherzer C; Jiménez Muñoz P; Ramsey S; Carey KB; Ranney ML; Clark S; Rich J; Langdon KJ
J Addict Dis; 2024; 42(1):24-32. PubMed ID: 36325942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
